CDC Provides Additional Supporting Information on New Data Reporting Requirements for Clinical Laboratories
Four important statements from a June 8 CDC clinical laboratory call covering COVID-19 test data reporting requirements.
COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
Four important statements from a June 8 CDC clinical laboratory call covering COVID-19 test data reporting requirements.
As of June 12, 2020, the FDA had authorized 135 COVID-19 tests under emergency use authorization (EUA), which include 114 molecular tests, 20 antibody tests, and 1 antigen test. The FDA has also released a new interactive tool designed to assist in identifying COVID-19 testing supply deficiencies and alternatives.
The FDA addresses concerns of unreliable tests by providing a new tool to support their evaluation of SARS-CoV-2 diagnostic tests.
SARS-CoV-2 test reporting requirements just multiplied. Clinical laboratories are on a deadline now.
Introduction to commercially manufactured SARS-CoV-2 serology tests listed with the status of “Removed – Should Not Be Distributed.”
While not specifically addressed by CMS, the U.S. Department of Health and Human Services (HHS) may fine non-compliant institutions up to $300 per day.
Four important statements from a June 8 CDC clinical laboratory call covering COVID-19 test data reporting requirements.
As of June 12, 2020, the FDA had authorized 135 COVID-19 tests under emergency use authorization (EUA), which include 114 molecular tests, 20 antibody tests, and 1 antigen test. The FDA has also released a new interactive tool designed to assist in identifying COVID-19 testing supply deficiencies and alternatives.
The FDA addresses concerns of unreliable tests by providing a new tool to support their evaluation of SARS-CoV-2 diagnostic tests.
SARS-CoV-2 test reporting requirements just multiplied. Clinical laboratories are on a deadline now.
Introduction to commercially manufactured SARS-CoV-2 serology tests listed with the status of “Removed – Should Not Be Distributed.”
While not specifically addressed by CMS, the U.S. Department of Health and Human Services (HHS) may fine non-compliant institutions up to $300 per day.